logo
Book a meeting
NYBC Ventures

Nybc Ventures

Hospital & Health Care, 310 E 67th St, New York, 10065, United States, 11-50 Employees

nybc.org/vtd-overview

  • LinkedIn

phone no Phone Number: +17*********

Who is NYBC VENTURES

Taking an agnostic approach to financing vehicles and structures and employing a model of patient capital, we have developed streamlined scientific and investment due diligence teams to e...

Read More

lock icon Get Full Access
map
  • 310 E 67th St, New York, New York, 10065, United States Headquarters: 310 E 67th St, New York, New York, 10065, United States
  • 2022 Date Founded: 2022
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $250 Million to $500 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Hospital & Health Care

SIC SIC Code: 8071 | NAICS Code: 621399 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from NYBC VENTURES

NYBC Ventures Org Chart and Mapping

Employees
Wanbo Tai

Wanbo Tai

Postdoctoral Researcher

See Full Org Chart arrow
email-formate-icon
View Email Formats for NYBC Ventures
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding NYBC Ventures

Answer: NYBC Ventures's headquarters are located at 310 E 67th St, New York, 10065, United States

Answer: NYBC Ventures's phone number is +17*********

Answer: NYBC Ventures's official website is https://nybc.org/vtd-overview

Answer: NYBC Ventures's revenue is $250 Million to $500 Million

Answer: NYBC Ventures's SIC: 8071

Answer: NYBC Ventures's NAICS: 621399

Answer: NYBC Ventures has 11-50 employees

Answer: NYBC Ventures is in Hospital & Health Care

Answer: NYBC Ventures contact info: Phone number: +17********* Website: https://nybc.org/vtd-overview

Answer: Taking an agnostic approach to financing vehicles and structures and employing a model of patient capital, we have developed streamlined scientific and investment due diligence teams to evaluate investment and collaborative opportunities in benign hematology, infectious diseases, transfusion medicine, cell therapy, and regenerative medicine.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access